Tarlatamab (Imdelltra) approved by FDA: new standard for small cell lung cancer
FDA fully approved tarlatamab for second-line therapy of small cell lung cancer after the DeLLphi-304 study. Learn about the breakthrough in treatment and new options for patients.
